Axio Data Monitoring Committee
Data monitoring and safety oversight platform for clinical trials
Company profile
Company profile
Cytel is a global clinical research organization that delivers advanced analytics, data science, and software solutions to pharmaceutical and biotechnology companies throughout the drug development lifecycle. The company specializes in innovative trial design methodologies including adaptive trial designs, Bayesian approaches, and model-informed drug development. Cytel's comprehensive service portfolio spans discovery and preclinical research, Phase I-III clinical trials, commercialization strategies, and real-world evidence generation. The organization offers strategic consulting, functional service provider models, and project-based analytical solutions tailored to client needs. Cytel's proprietary software platforms include East Horizon for trial design, the Xact software suite (including StatXact), Enforesys for trial implementation, and LiveSLR for systematic literature reviews. The company serves diverse therapeutic areas with particular expertise in rare diseases, oncology, and central nervous system disorders. Cytel provides specialized capabilities in health economics and outcomes research (HEOR), market access strategy, regulatory compliance, data monitoring committees, and real-world data analytics. Their solutions integrate advanced statistical methods with regulatory expertise to optimize trial efficiency, enhance probability of success, and accelerate time to market for new therapeutics.
Company description Cytel official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Cloud Saas · On Premise deployment with recorded integration context.
Company milestones
Company milestone context is currently being developed.
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Data monitoring and safety oversight platform for clinical trials
Platform for clinical trial design and simulation
Trial implementation and decision support software
Software for systematic literature reviews in clinical research
Statistical software for clinical trial analysis
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Human vaccines & immunotherapeutics · Dec 1, 2026
Incidence of New Malignancies in Severe Asthma: Comparison of Real-World Patients Treated with Benralizumab, Other Biologics, or Non-biologics.Pulmonary therapy · Aug 28, 2026
A health-economic assessment of the impact of different RSVpreF maternal vaccine strategies to prevent RSV infections among young infants, in France: EPIPACT.Vaccine · Aug 21, 2026
Risk factors and cognitive domain markers of progression in subjective cognitive decline.Journal of Alzheimer's disease : JAD · Aug 12, 2026
A real-world study on hospital and economic burden of dengue fever in French overseas territories.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · Jul 25, 2026
A Matching-Adjusted Indirect Comparison of PET-Guided BrECADD Versus PET-Guided ABVD, BEACOPP, and eBEACOPP in Advanced Hodgkin Lymphoma.Advances in therapy · Jul 23, 2026
Clinical validation
NCT03840395 · Sponsor · TERMINATED
Videofluoroscopic Swallowing Study (VFSS)NCT03387267 · Sponsor · TERMINATED
Pharyngeal Electrical Stimulation Evaluation for Dysphagia After StrokeNCT03358810 · Sponsor · COMPLETED
Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild SymptomsNCT04727424 · Sponsor · UNKNOWN
Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.NCT04731298 · Sponsor · TERMINATED
A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplantNCT04494061 · Sponsor · TERMINATED
Regulatory
No linked records are currently available.
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Recent articles published on Cytel's official website.
No Company updates are currently listed.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.